Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)

Hideki Kato; Masaomi Nangaku; Hideki Hirakata; Takashi Wada; Terumasa Hayashi; Hiroshi Sato; Yasushi Yamazaki; Takao Masaki; Tatsuo Kagimura; Hiroyasu Yamamoto; Hiroki Hase; Masahiro Kamouchi; Enyu Imai; Kyoichi Mizuno; Manabu Iwasaki; Tadao Akizawa; Yoshiharu Tsubakihara; Shoichi Maruyama; Ichiei Narita

doi:10.1007/s10157-017-1461-2

Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)

Hideki Kato, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Terumasa Hayashi, Hiroshi Sato, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura, Hiroyasu Yamamoto, Hiroki Hase, Masahiro Kamouchi, Enyu Imai, Kyoichi Mizuno, Manabu Iwasaki, Tadao Akizawa, Yoshiharu Tsubakihara, Shoichi Maruyama, Ichiei Narita

医療経営・管理学

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

抄録

The article Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial), written by Hideki Kato, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Terumasa Hayashi, Hiroshi Sato, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura, Hiroyasu Yamamoto, Hiroki Hase, Masahiro Kamouchi, Enyu Imai, Kyoichi Mizuno, Manabu Iwasaki, Tadao Akizawa, Yoshiharu Tsubakihara, Shoichi Maruyama, and Ichiei Narita was originally published electronically on the publisher’s internet portal (currently SpringerLink) on June 28, 2017 without open access.

本文言語	英語
ページ（範囲）	85-86
ページ数	2
ジャーナル	Clinical and Experimental Nephrology
巻	22
号	1
DOI	https://doi.org/10.1007/s10157-017-1461-2
出版ステータス	出版済み - 2月 1 2018

!!!All Science Journal Classification (ASJC) codes

生理学
腎臓病学
生理学（医学）

文献へのアクセス

10.1007/s10157-017-1461-2

他のファイルとリンク

フィンガープリント

「Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Kato, H., Nangaku, M., Hirakata, H., Wada, T., Hayashi, T., Sato, H., Yamazaki, Y., Masaki, T., Kagimura, T., Yamamoto, H., Hase, H., Kamouchi, M., Imai, E., Mizuno, K., Iwasaki, M., Akizawa, T., Tsubakihara, Y., Maruyama, S., & Narita, I. (2018). Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4). Clinical and Experimental Nephrology, 22(1), 85-86. https://doi.org/10.1007/s10157-017-1461-2

Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4). / Kato, Hideki; Nangaku, Masaomi; Hirakata, Hideki その他.
In: Clinical and Experimental Nephrology, Vol. 22, No. 1, 01.02.2018, p. 85-86.

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

Kato, H, Nangaku, M, Hirakata, H, Wada, T, Hayashi, T, Sato, H, Yamazaki, Y, Masaki, T, Kagimura, T, Yamamoto, H, Hase, H, Kamouchi, M, Imai, E, Mizuno, K, Iwasaki, M, Akizawa, T, Tsubakihara, Y, Maruyama, S & Narita, I 2018, 'Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)', Clinical and Experimental Nephrology, vol. 22, no. 1, pp. 85-86. https://doi.org/10.1007/s10157-017-1461-2

Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H その他. Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4). Clinical and Experimental Nephrology. 2018 2月 1;22(1):85-86. doi: 10.1007/s10157-017-1461-2

Kato, Hideki ; Nangaku, Masaomi ; Hirakata, Hideki その他. / Erratum to : Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4). In: Clinical and Experimental Nephrology. 2018 ; Vol. 22, No. 1. pp. 85-86.

@article{daff50f72ffa4c31863e0c66f05a3d1a,

title = "Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)",

abstract = "The article Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial), written by Hideki Kato, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Terumasa Hayashi, Hiroshi Sato, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura, Hiroyasu Yamamoto, Hiroki Hase, Masahiro Kamouchi, Enyu Imai, Kyoichi Mizuno, Manabu Iwasaki, Tadao Akizawa, Yoshiharu Tsubakihara, Shoichi Maruyama, and Ichiei Narita was originally published electronically on the publisher{\textquoteright}s internet portal (currently SpringerLink) on June 28, 2017 without open access.",

author = "Hideki Kato and Masaomi Nangaku and Hideki Hirakata and Takashi Wada and Terumasa Hayashi and Hiroshi Sato and Yasushi Yamazaki and Takao Masaki and Tatsuo Kagimura and Hiroyasu Yamamoto and Hiroki Hase and Masahiro Kamouchi and Enyu Imai and Kyoichi Mizuno and Manabu Iwasaki and Tadao Akizawa and Yoshiharu Tsubakihara and Shoichi Maruyama and Ichiei Narita",

note = "Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2018",

month = feb,

day = "1",

doi = "10.1007/s10157-017-1461-2",

language = "English",

volume = "22",

pages = "85--86",

journal = "Clinical and Experimental Nephrology",

issn = "1342-1751",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Erratum to

T2 - Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)

AU - Kato, Hideki

AU - Nangaku, Masaomi

AU - Hirakata, Hideki

AU - Wada, Takashi

AU - Hayashi, Terumasa

AU - Sato, Hiroshi

AU - Yamazaki, Yasushi

AU - Masaki, Takao

AU - Kagimura, Tatsuo

AU - Yamamoto, Hiroyasu

AU - Hase, Hiroki

AU - Kamouchi, Masahiro

AU - Imai, Enyu

AU - Mizuno, Kyoichi

AU - Iwasaki, Manabu

AU - Akizawa, Tadao

AU - Tsubakihara, Yoshiharu

AU - Maruyama, Shoichi

AU - Narita, Ichiei

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The article Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial), written by Hideki Kato, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Terumasa Hayashi, Hiroshi Sato, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura, Hiroyasu Yamamoto, Hiroki Hase, Masahiro Kamouchi, Enyu Imai, Kyoichi Mizuno, Manabu Iwasaki, Tadao Akizawa, Yoshiharu Tsubakihara, Shoichi Maruyama, and Ichiei Narita was originally published electronically on the publisher’s internet portal (currently SpringerLink) on June 28, 2017 without open access.

AB - The article Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial), written by Hideki Kato, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Terumasa Hayashi, Hiroshi Sato, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura, Hiroyasu Yamamoto, Hiroki Hase, Masahiro Kamouchi, Enyu Imai, Kyoichi Mizuno, Manabu Iwasaki, Tadao Akizawa, Yoshiharu Tsubakihara, Shoichi Maruyama, and Ichiei Narita was originally published electronically on the publisher’s internet portal (currently SpringerLink) on June 28, 2017 without open access.

UR - http://www.scopus.com/inward/record.url?scp=85028955991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028955991&partnerID=8YFLogxK

U2 - 10.1007/s10157-017-1461-2

DO - 10.1007/s10157-017-1461-2

M3 - Comment/debate

C2 - 28875480

AN - SCOPUS:85028955991

SN - 1342-1751

VL - 22

SP - 85

EP - 86

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

IS - 1

ER -